The study also showed that cells transplanted to the spinal cord (intrathecal injection) were associated with significantly slower disease progression rates, compared to cells delivered into the bloodstream.
The review “Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis” was published in the journal Stem Cells International.
The use of adult stem cell therapy, such as MSCs, as a therapeutic strategy for MS is increasing. MSCs are found in several parts of the body, including the bone marrow, skin, and fat tissue.
Autologous MSCs transplant involves collecting a patient’s MSCs and expanding their numbers in the lab. Cells are then infused back into the patient’s blood (intravenous injection), or into the fluid surrounding the spinal cord (intrathecal injection).
In this review, researchers in China performed a meta-analysis of published studies across several databases to assess the effectiveness and safety of autologous MSCs transplant in MS.
In eight studies the MSCs were collected from the bone marrow, and in one study from the fat (adipose) tissue. In three studies cells were transplanted into the patient’s blood (intravenous injection), and in five into the fluid surrounding the spinal cord (intrathecal injection). One study used both strategies for the transplant.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?